The content of this presentation reflects the views and opinions of the presenter alone and does not necessarily represent those of any organization. CPFF and the presenter have not received any funding or support from any company in the creation of this video.
**Nerandomilast is an investigational product still under development and has not received market authorization from Health Canada.**
Discover how Nerandomilast, a new pulmonary fibrosis treatment now under government review, could transform care for IPF and PPF patients.
A new medication called Nerandomilast is currently undergoing government review as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). In this video, Dr. Shane Shapera shares the latest updates on pulmonary fibrosis diagnosis and treatment, the challenges and benefits of current therapies, and how Nerandomilast could change the future of PF care. Watch now to stay informed and discover what’s on the horizon for pulmonary fibrosis patients and families.
About Dr. Shane Shapera, Respirologist
Dr. Shane Shapera is an Associate Professor and Clinician Educator in the Faculty of Medicine at the University of Toronto. He is the Director of the Interstitial Lung Diseases (ILD) Program at Toronto General Hospital, which is part of the University Health Network (UHN). He also works with the Toronto Lung Transplant Program, providing pre-lung transplant assessments for patients with interstitial lung disease.
Dr. Shapera has expertise in various aspects of ILD, including idiopathic pulmonary fibrosis (IPF), systemic scleroderma interstitial lung disease (SSc-ILD), and myositis-associated lung disease. He has contributed to ILD research and care in Canada, supported by the CPFF Robert Davidson Fellowship Program, and has delivered numerous educational webinars on ILD-related topics.